Development of an in vitro immunoassay for Sec61-beta as a biomarker screening colorectal cancer

• Main Authors: Xuan Pei Sun, 孫瑄珮
• Other Authors: E. C. Chan
• Format: Others
• Published: 2011
• Online Access: http://ndltd.ncl.edu.tw/handle/10414383671349721425

碩士 === 長庚大學 === 醫學生物技術暨檢驗學系 === 99 === According to statistical data of Department of Health, Executive Yuan, R.O.C. (Taiwan), colorectal cancer (CRC) is the third common malignancy in Taiwan. Clinical symptoms are inconspicuous at an early stage of CRC, and it is always combine with metastasis at an advantage stage with 5 years survival rates lower than 10% in patients. Detection of the CRC during an early stage, that can decrease both the incidence and mortality of CRC. A previous study showed (unpublished), Sec61-β, a transmembrane protein that transported proteins pass the endoplasmic reticulum membrane, was overexpressed in 60% of tumor tissues from CRC patients. The western blot data showed 78% sensitivity and 69% specificity. Thus, our study expects to develop an ELISA kit to detect Sec61-β protein in CRC patients’ plasma. First, we prepared rabbit anti-Sec61-beta antibody against full length Sec61-β protein. But it showed low P value (P value= 0.4) in ELISA test. Therefore, We depart Sec61-β protein into two proteins by cloning two cDNA fragments , thus, we expect to obtain two different polyclonal antibodies against different Sec61-β protein site to improve the assay sensitivity and specificity.